ITPRIPL1 and rhabdomyosarcoma: To validate the specificity of the anti-ITPRIPL1 antibody further, we performed immunoblot and flow cytometry on different human tumors, including melanoma A375, rhabdomyosarcoma A-204, RD, non-small cell lung cancer A549, H1299, breast cancer MBA-MD-231, MCF7 and colorectal carcinoma HCT116, SW480, SW1116 (Figures 1C, D, Supplementary Figure S1C).